BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Breaking News: Try BioWorld for free for two weeks
See today's BioWorld Science
Home
» NR2F6 antagonist TES-4207 shows promising preclinical results for cancer
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
EFMC-ISMC 2022
NR2F6 antagonist TES-4207 shows promising preclinical results for cancer
Sep. 9, 2022
No Comments
The interaction of immune checkpoints, such as programmed cell death protein 1 (PD-1) or cytotoxic T-lymphocyte antigen-4 (CTLA-4), with their ligands leads to T-cell deactivation, allowing cancer cells to escape from the immune system.
BioWorld Science
Conferences
Immunotherapy
Cancer